Rituximab treatment in a case of antisynthetase syndrome with severe interstitial lung disease and acute respiratory failure
Open Access
- 1 January 2011
- journal article
- Published by Mattioli1885 in Multidisciplinary Respiratory Medicine
- Vol. 6 (3), 183-188
- https://doi.org/10.1186/2049-6958-6-3-183
Abstract
We present a case of severe interstitial pneumonitis, mild polyarthritis and polymyositis, and Raynaud's syndrome with the presence of anti-Jo-1 antibodies, which had been diagnosed as anti-synthetase syndrome. The presence, however, of anti-Ro/SSA antibodies led us to understand that we were dealing here with a more severe form of interstitial lung disease. The patient was treated for acute respiratory failure but he showed resistance to glucocorticoids and cyclosporine. Thus, he was treated with infusions of anti-CD20 therapy (rituximab): his clinical conditions improved very rapidly and a significant decrease in the activity of pulmonary disease was detected using high-resolution computerized tomography (HRCT) of the thorax and pulmonary function tests.Keywords
This publication has 8 references indexed in Scilit:
- Pneumopathie aiguë sévère révélatrice d’un syndrome des anticorps antisynthétasesLa Revue de Médecine Interne, 2009
- Rituximab treatment of the anti-synthetase syndrome—a retrospective case seriesRheumatology, 2009
- Rituximab in life threatening antisynthetase syndromeRheumatology International, 2009
- Rituximab for refractory polymyositis: an open-label prospective study.2007
- Rituximab in the treatment of antisynthetase syndromeAnnals Of The Rheumatic Diseases, 2005
- Rituximab in the treatment of dermatomyositis: An open‐label pilot studyArthritis & Rheumatism, 2005
- Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2004
- Antisynthetase syndromeJoint Bone Spine, 2003